IGC Pharma (NYSEMKT:IGC – Free Report) had its price objective raised by Ascendiant Capital Markets from $3.50 to $3.75 in a report published on Tuesday, Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.
IGC Pharma Stock Performance
Shares of IGC opened at $0.35 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.16 and a current ratio of 1.77. The stock has a market capitalization of $26.11 million, a price-to-earnings ratio of -1.57 and a beta of 1.27.
About IGC Pharma
Further Reading
- Five stocks we like better than IGC Pharma
- How to Use the MarketBeat Stock Screener
- Emerging Markets: What They Are and Why They Matter
- Investing in Construction Stocks
- Recession or Not, These 3 Stocks Are Winners
- How Investors Can Find the Best Cheap Dividend Stocks
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for IGC Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGC Pharma and related companies with MarketBeat.com's FREE daily email newsletter.